argenx SE on Tuesday said the U.S. Food and Drug Administration has accepted for priority review a supplemental Biologics License Application (sBLA) for Vyvgart for the treatment of adults with acetylcholine receptor antibody-seronegative generalized myasthenia gravis.
The application has been granted a Prescription Drug User Fee Act target action date of May 10, 2026.
The sBLA is supported by data from the Phase 3 ADAPT SERON study evaluating Vyvgart in adults with AChR antibody-seronegative generalized myasthenia gravis.
Vyvgart is currently approved in the United States, the European Union, China and Canada for the treatment of adults with generalized myasthenia gravis who are anti-acetylcholine receptor antibody positive. In Japan, the drug is approved for adults with gMG who have shown an inadequate response to steroids or non-steroidal immunosuppressive therapies.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.